Ind Swift Laboratories Ltd vs Sotac Pharmaceuticals Ltd Stock Comparison

Home

Insights

Stock Comparison

Last Updated on: May 12, 2026

Key Highlights

The Latest Trading Price of Ind-Swift Laboratories Ltd is ₹ 138.65 as of 12 May 10:45 . The P/E Ratio of Ind-Swift Laboratories Ltd changed from 6.9 on March 2023 to 2.3 on March 2025 . This represents a CAGR of -30.66% over 3 yearsThe P/E Ratio of Sotac Pharmaceuticals Ltd changed from 31.3 on March 2024 to 16.4 on March 2025 . This represents a CAGR of -27.61% over 2 years The Market Cap of Ind-Swift Laboratories Ltd changed from ₹ 425.72 crore on March 2021 to ₹ 509.08 crore on March 2025 . This represents a CAGR of 3.64% over 5 yearsThe Market Cap of Sotac Pharmaceuticals Ltd changed from ₹ 133.71 crore on March 2024 to ₹ 131.22 crore on March 2025 . This represents a CAGR of -0.94% over 2 years The revenue of Ind-Swift Laboratories Ltd for the Dec '25 is ₹ 178.43 crore as compare to the Sep '25 revenue of ₹ 170.5 crore. This represent the growth of 4.65% The revenue of Sotac Pharmaceuticals Ltd for the Dec '25 is ₹ 0 crore as compare to the Sep '25 revenue of ₹ 0 crore. This represent the decline of 0% The ebitda of Ind-Swift Laboratories Ltd for the Dec '25 is ₹ 25.9 crore as compare to the Sep '25 ebitda of ₹ 19.34 crore. This represent the growth of 33.92% The ebitda of Sotac Pharmaceuticals Ltd for the Dec '25 is ₹ 0 crore as compare to the Sep '25 ebitda of ₹ 0 crore. This represent the decline of 0% The net profit of Ind-Swift Laboratories Ltd changed from ₹ 1.01 crore to ₹ 9.52 crore over 7 quarters. This represents a CAGR of 260.37% The net profit of Sotac Pharmaceuticals Ltd changed from ₹ 1.35 crore to ₹ 0 crore over 7 quarters. This represents a CAGR of -100.00% The Dividend Payout of Ind-Swift Laboratories Ltd changed from 0 % on March 2021 to 0 % on March 2025 . This represents a CAGR of 0.0% over 5 yearsThe Dividend Payout of Sotac Pharmaceuticals Ltd changed from 13.94 % on March 2022 to 0 % on March 2025 . This represents a CAGR of -100.00% over 4 years .

About Ind-Swift Laboratories Ltd

Ind-Swift Laboratories Limited is a part of the Ind-Swift Group and is based at Chandigarh, Punjab, India.
The Company is one of the leading manufacturers of APIs catering to global and domestic formulators.
Based in Chandigarh, India, the Company operated two advanced manufacturing facilities in Derabassi and Jammu, adhering to international standards.
Ind-Swift Laboratories Ltd. is recognised globally as a leader in the Macrolide Antibiotic sector, and its products are well-regarded by major pharmaceutical formulators worldwide. Ind-Swift Laboratories Limited was incorporated on January 4, 1995 as a joint venture between Ind-Swift Ltd and Punjab State Industrial Development Corporation.
Later, Ind-Swift purchased Punjab State Industrial Development Corporation equity to emerge as a single largest shareholder in the company.

About Sotac Pharmaceuticals Ltd

Sotac Pharmaceuticals Limited was originally formed and registered as a Partnership Firm under the Partnership Act, 1932 in the name of 'M/s Sotac Pharmaceuticals', pursuant to a Deed of Partnership dated October 28, 2015.
Thereafter 'M/s.
Sotac Pharmaceuticals' was converted from Partnership Firm to a Private Limited Company in the name of 'Sotac Pharmaceuticals Private Limited' dated December 18, 2015 from the Assistant Registrar of Companies, Gujarat.
Later on, Company converted into a Public Limited Company and the name of Company was changed to 'Sotac Pharmaceuticals Limited' dated November 22, 2022 issued by Registrar of Companies, Ahmedabad. The Company is a part of SOTAC Group, based at Gujarat and is engaged in manufacturing of pharmaceutical products for different marketers on loan license or contract manufacturing basis.

FAQs for the comparison of Ind-Swift Laboratories Ltd and Sotac Pharmaceuticals Ltd

Which company has a larger market capitalization, Ind-Swift Laboratories Ltd or Sotac Pharmaceuticals Ltd?

Market cap of Ind-Swift Laboratories Ltd is 1,202 Cr while Market cap of Sotac Pharmaceuticals Ltd is 117 Cr

What are the key factors driving the stock performance of Ind-Swift Laboratories Ltd and Sotac Pharmaceuticals Ltd?

The stock performance of Ind-Swift Laboratories Ltd and Sotac Pharmaceuticals Ltd is primarily driven by its robust global client base, consistent revenue growth, strong operational efficiency, strategic investments in digital transformation, client acquisition, and the overall health of the industry. Both companies' performances are also influenced by macroeconomic conditions, currency fluctuations, and industry-specific trends.

What are the recent stock price for Ind-Swift Laboratories Ltd and Sotac Pharmaceuticals Ltd?

As of May 12, 2026, the Ind-Swift Laboratories Ltd stock price is INR ₹138.45. On the other hand, Sotac Pharmaceuticals Ltd stock price is INR ₹106.0.

How do dividend payouts of Ind-Swift Laboratories Ltd and Sotac Pharmaceuticals Ltd compare?

To compare the dividend payouts of Ind-Swift Laboratories Ltd and Sotac Pharmaceuticals Ltd, examine their dividend payout ratio, which indicates how much the companies pay out relative to their share price and earnings. Moreover, consider the consistency and growth of their dividends to gauge their commitment towards returning value to the respective shareholders.

Disclaimer: This information provided above is for informational purposes only and does not constitute investment advice. We use third-party data and recommend conducting thorough research and consulting a certified financial advisor before making investment decisions. We do not endorse specific stocks. Make decisions based on your own research and professional guidance.